<DOC>
	<DOCNO>NCT00295880</DOCNO>
	<brief_summary>Rationale : Giving chemotherapy total-body irradiation donor umbilical cord blood transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor 's umbilical cord blood inject patient 's bone marrow may help make stem cell , red blood cell , white blood cell , platelet . Purpose : This phase I/II trial study side effect donor umbilical cord blood transplant give directly bone marrow see well work treat patient hematologic cancer .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplant By Injection Into Bone Marrow Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>Objectives : Primary - Determine safety , term infusional toxicity , myeloablative unrelated donor double-unit umbilical cord blood ( UCB ) transplantation via intra-bone marrow injection ( IBMI ) patient advance high-risk hematologic malignancy . - Determine whether treatment regimen improve time neutrophil engraftment ( compare historical control ) patient . Secondary - Determine incidence sustain donor engraftment patient treat regimen . - Determine relative contribution UCB unit initial sustain donor engraftment patient . - Determine incidence grade II-IV grade III-IV acute graft-vs-host disease ( GVHD ) chronic GVHD patient treat regimen . - Determine incidence day 100 180 transplant-related mortality patient treat regimen . - Determine probability survival 100 day 1 year post-transplantation patient . Outline : This nonrandomized study . Patients receive myeloablative conditioning regimen . Patients also receive immunosuppression , growth factor , supportive care protocol MT2005-10 ( NCT00309842 ) . Patients receive 2 unit donor umbilical cord blood ( UCB ) intra-bone marrow injection ( IBMI ) 10 minute day 0 . If IBMI procedure possible , UCB unit give intravenously ( IV . ) After completion study therapy , patient follow periodically 5 year . Projected Accrual : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>Acute myeloid leukemia ( AML ) : high risk CR1 Acute lymphocytic leukemia ( ALL ) : high risk CR1 [ ( 9 ; 22 ) , ( 1:19 ) , ( 4 ; 11 ) MLL rearrangement ] &gt; 1 cycle obtain CR ; CR2+ . All patient must CR defined hematological recovery , AND &lt; 5 % blast light microscopy within bone marrow cellularity â‰¥15 % . Chronic myelogenous leukemia ( CML ) exclude refractory blast crisis . To eligible first chronic phase ( CP1 ) patient must fail intolerant imatinib mesylate . Myelodysplasia ( MDS ) IPSS Int2 High risk ( i.e . RAEB , RAEBt ) refractory anemia severe pancytopenia high risk cytogenetics . Chronic lymphocytic leukemia/small lymphocytic lymphoma ( CLL/SLL ) , marginal zone Bcell lymphoma follicular lymphoma progress least two prior therapy . Patients bulky disease ( nodal mass great 5 cm ) . Lymphoplasmacytic lymphoma , mantlecell lymphoma , prolymphocytic leukemia eligible initial therapy CR1+ PR1+ . Large cell NHL &gt; CR2/ &gt; PR2 . Patients CR2/PR2 initial short remission ( &lt; 6 month ) eligible . Lymphoblastic lymphoma . Multiple myeloma beyond PR2 . Karnofsky performance status ( PS ) 90100 % ( adult ) Lansky PS 50100 % ( child ) Acceptable organ function Active infection time transplantation History HIV infection Pregnant breast feeding . Chemotherapy refractory large cell high grade NHL ( ie progressive disease &gt; 2 salvage regimen ) Extensive prior therapy include &gt; 12 month alkylator therapy &gt; 6 month alkylator therapy extensive radiation . Diffuse myelofibrosis BM ( bone marrow ) ( severity ) regardless primary diagnosis ( focal fibrosis acceptable provide involve &lt; 20 % BM volume ) . History pelvic irradiation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>adult diffuse large cell lymphoma</keyword>
	<keyword>adult diffuse mixed cell lymphoma</keyword>
	<keyword>adult diffuse small cleave cell lymphoma</keyword>
	<keyword>adult lymphoblastic lymphoma</keyword>
	<keyword>grade 3 follicular lymphoma</keyword>
	<keyword>mantle cell lymphoma</keyword>
	<keyword>childhood large cell lymphoma</keyword>
	<keyword>childhood lymphoblastic lymphoma</keyword>
	<keyword>adult acute lymphoblastic leukemia</keyword>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory cytopenia</keyword>
	<keyword>childhood acute myeloid leukemia</keyword>
	<keyword>adult immunoblastic large cell lymphoma</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>childhood small noncleaved cell lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>